Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients
International Journal of Molecular Sciences · 30.06.2023 · 24 (13) · 10922
DOI: 10.3390/ijms241310922 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.06.2023. Verfasst von Montalbano Mauro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555-5302, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, National Institute of Environmental Health Science (NIEHS), Surgery Department ay UTMB.
Abstract (Originalsprache)
Glypican-3 (GPC-3) is a heparin sulfate proteoglycan located extracellularly and anchored to the cell membrane of transformed hepatocytes. GPC-3 is not expressed in normal or cirrhotic liver tissue but is overexpressed in hepatocellular carcinoma (HCC). Because of this, GPC-3 is one of the most important emerging immunotargets for treatment and as an early detection marker of HCC. To determine if GPC-3 domains associated with serum small extracellular vesicles (sEVs) could be used as an HCC diagnostic marker, we predicted in silico GPC-3 structural properties and tested for the presence of its full-length form and/or cleaved domains in serum sEVs isolated from patients with HCC. Structural analysis revealed that the Furin cleavage site of GPC-3 is exposed and readily accessible, suggesting the facilitation of GPC-3 cleavage events. Upon isolation of sEVs from both hepatocytes, culture media and serum of patients with HCC were studied for GPC-3 content. This data suggests that Furin-dependent GPC-3 cleaved domains could be a powerful tool for detection of initial stages of HCC and serve as a predictor for disease prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555-5302, USA.
- Molecular Informatics Group, Fondazione Ri.MED., 90133 Palermo, Italy.
- John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX 77555-5302, USA.
- Rutgers Health, Department of Cardiac Surgery, New Brunswick, NJ 08901, USA.
- Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555-5302, USA.
- Department of Neurobiology, University of Texas Medical Branch, Galveston, TX 77555-5302, USA.
ORCID-Profile: Montalbano Mauro, Perricone Ugo
Förderung
- NIEHS NIH HHS
- National Institute of Environmental Health Science (NIEHS)
- Surgery Department ay UTMB
Zitieren
APA
Mauro, M., Ugo, P., Walton, Z., Ali, S., Rastellini, C., & Cicalese, L. (2023). Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients. International Journal of Molecular Sciences, 24(13), 10922. https://doi.org/10.3390/ijms241310922
Vancouver
Mauro M, Ugo P, Walton Z, Ali S, Rastellini C, Cicalese L. Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients. International Journal of Molecular Sciences. 2023;24(13):10922. doi:10.3390/ijms241310922
BibTeX
@article{Mauro2023,
author = {Mauro, Montalbano and Ugo, Perricone and Walton, Zachary and Ali, Shirafkan and Rastellini, Cristiana and Cicalese, Luca},
title = {Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {13},
pages = {10922},
doi = {10.3390/ijms241310922}
}
EUVIMED